Skip to main content
Kuros Biosciences Ltd. logo

Kuros Biosciences Ltd. — Investor Relations & Filings

Ticker · KURN ISIN · CH0325814116 LEI · 5299006U5POB2AVTT709 SW Manufacturing
Open in API
Filings indexed 207 across all filing types
Latest filing 2022-10-11 Investor Presentation
Country CH Switzerland
Listing SW KURN

About Kuros Biosciences Ltd.

https://kurosbio.com/

Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.

Recent filings

Filing Released Lang Actions
Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting
Investor Presentation Classification · 95% confidence The document is a press release dated 11.10.2022 announcing that Kuros Biosciences will present clinical data for its product MagnetOs at the NASS 2022 Annual Meeting and simultaneously announcing the commercial launch of MagnetOs Flex Matrix. This type of announcement, which details upcoming presentations of scientific/clinical data and product updates, is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT), and it focuses heavily on presenting scientific findings and market strategy to investors, the most fitting category is Investor Presentation (IP). It is not a simple announcement of a report release (RPA) because it contains substantial, detailed information about the data and product launch itself, rather than just stating a report is available.
2022-10-11 English
Kuros Biosciences Appoints Chris Fair as Chief Operating Officer
Board/Management Information Classification · 100% confidence The document is an 'Ad hoc announcement' released on October 3, 2022, detailing the appointment of Chris Fair as Chief Operating Officer (COO) and his subsequent resignation from the Board of Directors. This type of announcement concerns changes in senior management personnel. Based on the provided definitions, the category 'Board/Management Information (Code: MANG)' is the most appropriate fit, as it covers 'Announcement of changes in the company's board of directors or senior management.' The document is not a formal financial report (like 10-K or IR) or a general regulatory filing (RNS), but a specific personnel announcement.
2022-10-03 English
Kuros Biosciences Appoints Chris Fair as Chief Operating Officer
Board/Management Information Classification · 100% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and its primary content is the announcement that Kuros Biosciences has appointed Chris Fair as Chief Operating Officer (COO). This involves a change in senior management personnel. This directly aligns with the definition for Board/Management Information (MANG), which covers 'Announcement of changes in the company's board of directors or senior management.' The document is not a full financial report (10-K, IR), an earnings release (ER), or a presentation (IP).
2022-10-03 English
Kuros Biosciences announces successful CHF 6.0 million private placement
Share Issue/Capital Change Classification · 99% confidence The document is an 'Ad-hoc' announcement dated September 15, 2022, titled 'Kuros Biosciences announces successful CHF 6.0 million private placement'. The content explicitly details the successful completion of a capital increase through the placement of new shares, including the price, the investors involved, and the resulting change in share capital. This activity directly relates to fundraising and changes in the company's capital structure. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP).
2022-09-15 English
Kuros Biosciences announces successful CHF 6.0 million private placement
Share Issue/Capital Change Classification · 99% confidence The document is an 'Ad hoc announcement' detailing the 'successful completion of a CHF 6.0 million capital increase through a private placement of 3,750,000 new shares'. This explicitly describes a financing activity, including the amount raised, the price, and the resulting capital structure change. This directly aligns with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it concerns a specific corporate finance event.
2022-09-15 English
Kuros Biosciences MagnetOs Bone Graft Successfully Achieves Three Key Milestones
Earnings Release Classification · 99% confidence The document is a press release dated August 23, 2022, detailing three key operational and clinical milestones achieved by Kuros Biosciences regarding its MagnetOs bone graft product (completion of enrolment in a clinical trial, first patient treated with a new variant, and reaching 10,000 patients treated). This type of announcement, focusing on operational progress, clinical updates, and commercial achievements, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Dividend Notice (DIV), it best fits the 'Earnings Release' category, which often includes key operational highlights preceding or accompanying formal financial reporting. Given the content focuses on clinical and commercial progress rather than just financial figures, it aligns closely with the spirit of an ER announcing performance milestones. Q3 2022
2022-08-23 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.